GlobeNewswire Inc.Apr 6, 1:00 PM ET▲ Positive
Budoprutug in mid-stage development with expected US approval by 2031; published long-term follow-up data showing sustained proteinuria control up to three years post-dosing.
Climb Bio news
$11.50−2.04%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Climb Bio
No recent articles focused on Climb Bio.
Also mentions CLYM
Articles that tag CLYM but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology